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Abstract
Axon regeneration in the injured adult CNS is reportedly inhibited by myelin-derived inhibitory molecules, after binding to a
receptor complex comprised of the Nogo-66 receptor (NgR1) and two transmembrane co-receptors p75/TROY and LINGO-1.
However, the post-injury expression pattern for LINGO-1 is inconsistent with its proposed function. We demonstrated that
AMIGO3 levels were significantly higher acutely than those of LINGO-1 in dorsal column lesions and reduced in models of
dorsal root ganglion neuron (DRGN) axon regeneration. Similarly, AMIGO3 levels were raised in the retina immediately after
optic nerve crush, whilst levels were suppressed in regenerating optic nerves, induced by intravitreal peripheral nerve
implantation. AMIGO3 interacted functionally with NgR1-p75/TROY in non-neuronal cells and in brain lysates, mediating
RhoA activation in response to CNS myelin. Knockdown of AMIGO3 in myelin-inhibited adult primary DRG and retinal
cultures promoted disinhibited neurite growth when cells were stimulated with appropriate neurotrophic factors. These
findings demonstrate that AMIGO3 substitutes for LINGO-1 in the NgR1-p75/TROY inhibitory signalling complex and
suggests that the NgR1-p75/TROY-AMIGO3 receptor complex mediates myelin-induced inhibition of axon growth acutely in
the CNS. Thus, antagonizing AMIGO3 rather than LINGO-1 immediately after CNS injury is likely to be a more effective
therapeutic strategy for promoting CNS axon regeneration when combined with neurotrophic factor administration.
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Introduction
CNS axon regeneration is limited by a low intrinsic growth
capacity of mature neurons and the presence of a non-permissive
environment in the injured adult CNS that inhibits axon growth
[1,2,3,4]. Three major inhibitory ligands exist in CNS myelin
including Nogo-A, myelin associated glycoprotein (MAG) and
oligodendrocyte myelin glycoprotein (OMgp), which collectively
account for the majority of CNS inhibitory activity [1,2,5,6]. All
three myelin inhibitors bind to a common receptor, Nogo-66
receptor (NgR1) that can signal inhibition and growth cone
collapse through the RhoGTPase pathway by associating with two
signal transducing binding partners, p75 (the low affinity
neurotrophin receptor) and LINGO-1 (leucine rich-repeat and
immunoglobulin domain-containing, Nogo receptor interacting
protein) [1,3,7,8,9,10]. While NgR1 and LINGO-1 are widely
expressed in CNS neurons [9,10], p75 expression is more
restricted. TROY, a TNF receptor family member that has a
broad pattern of expression in postnatal and adult neurons, was
identified as a substitute for p75 in the NgR1/p75/LINGO-1
receptor complex [11,12].
Other proteins that contain LINGO-1-like LRR motifs include
amphoterin (also known as HMGB1), a heparin-binding LRR
protein abundant in growth cones [13] and amphoterin-induced
gene and open reading frame 1 (AMIGO), along with AMIGO2
and AMIGO3 isoforms, that were isolated from rat brain and
shown to have neurite outgrowth promoting properties [14].
AMIGO, AMIGO2 and AMIGO3 are expressed in brain tissues
in adult mice, with AMIGO3 having a more widespread
distribution also being found in liver, kidney and spleen [14].
Expression of AMIGO correlates with the onset of CNS
myelination during postnatal development and localises to axonal
fibre tracts, while a substrate bound AMIGO-immunoglobulin
fusion protein which antagonizes AMIGO, promotes neurite
outgrowth of hippocampal neurons [14], but little is known about
the axogenic properties of AMIGO2 and AMIGO3.
Since LINGO-1 expression levels do not rise in the spinal cord
until 14 days after spinal cord injury [10], other NgR1 co-
receptors mediating axon growth inhibition are likely to be
expressed and function during the acute stages after CNS injury.
Here, we report using retinal ganglion cell (RGC) and dorsal root
ganglion neuron (DRGN) axotomy models that: (1), AMIGO3
mRNA and protein levels are preferentially and significantly raised
in DRGN and RGC immediately after central axotomy; (2),
depression of AMIGO3 expression correlates with dorsal column
(DC) and optic nerve regeneration; (3), AMIGO3 interacts with
PLOS ONE | www.plosone.org 1 April 2013 | Volume 8 | Issue 4 | e61878
NgR1 and p75/TROY in both transfected cells and rat and
human brain lysates, forming a functional receptor complex that
activates RhoGTP in cells exposed to CNS myelin extracts (CME);
and (4), siRNA-mediated knockdown of AMIGO3 significantly
enhances DRGN and RGC neurite outgrowth in CME-inhibited
cultures when stimulated with appropriate neurotrophic factors
(NTF). These results suggest that AMIGO3 substitutes for
LINGO-1 in centrally axotomized DRGN and RGC in the acute
phase of injury and that the NgR1-p75/TROY-AMIGO3
receptor complex mediates immediate axon growth inhibitory
responses to CNS myelin.
Materials and Methods
Ethics statement
This study was carried out in strict accordance to the UK
Animals Scientific Procedures Act, 1986 and all procedures were
licensed and approved by the UK Home Office and by the
University of Birmingham Ethical Review Sub-Committee. All
surgery was performed under inhalation anaesthesia using 5%
Isofluorane (IsoFlo, Abbott Animal Health, North Chicago, IL,
USA) for induction and 2% for maintenance. Animals were kept
in environmentally controlled designated and licenced animal
facility at the University of Birmingham and every effort was made
to minimise animal suffering throughout the study.
Regenerating and non-regenerating DRGN models
Regenerating and non-regenerating models were established as
described by us [15,16,17,18]. Briefly, experiments comprised 4
groups, each containing 10 adult female Sprague-Dawley rats
(180–220 g) (Charles River, Margate, UK) for each analytical
time-point and designated as: (1), uninjured control (intact); (2),
DC crush (non-regenerating DC model); (3), sciatic nerve (SN)
crush (regenerating SN model); and (4), preconditioning (p)SN
lesions 1 week before a DC crush (regenerating pSN+DC model).
Under inhalation anaesthesia, DC were crushed bilaterally at the
level of T8 using calibrated watchmaker’s forceps inserted through
the dorsal cord meninges to a depth of 1.5 mm. For SN injury, the
left SN was exposed at a mid-thigh level and crushed using needle
forceps at the level of the sacrotuberous ligament. One week
before a DC crush, SN lesions were performed as described above.
Animals were killed by CO2 exposure at 1 and 10 days post-lesion
(dpl) and the L4/L5 DRG harvested for RNA and protein analysis
by snap freezing in liquid nitrogen. For immunohistochemistry,
animals were intracardially perfused with 4% formaldehyde and
the L4/L5 DRG were processed as described later.
Regenerating and non-regenerating optic nerve (ON)
injury models
Regenerating and non-regenerating ON injury models, each
containing 12 animals, were established as described by us
[19,20,21,22]. Briefly, the ON of adult female 200–250 g Fischer
rats were crushed intraorbitally under inhalation anaesthesia,
using fine watchmakers forceps. The regenerating ON model
(ON-RM) group comprised animals that received intravitreal
implantation of 5 mm of freshly teased SN, held in place using
Sterispon gelatine sponge (Johnson and Johnson, New Jersey USA)
while the non-regenerating model (ON-NRM) received no
treatment after ON crush. The changes in AMIGO3 levels after
these two treatments were compared to intact controls. Sham
injured controls were also included, but these did not demonstrate
changes in AMIGO3 levels and therefore are not shown.
Microarray analysis
The rat genome AROSTM V3.0set (Operon Biotechnologies
GmbH, Cologne, Germany) containing 26,962 long mer probes
representing 22,012 genes and 27,044 gene transcripts was used
for the microarray analysis as described by us previously
[16,17,23]. Briefly, either Cy3 or Cy5-labelled oligonucleotide
probes were hybridised according to the manufacturer’s protocol
and slides were scanned with an Axon GenePix 4000B scanner
(Molecular Devices Ltd, Berkshire, UK). After subtracting
background fluorescence values for Cy3 or Cy5 channels in
GenePix, data was exported into GeneSpring GX7 (Agilent,
Berkshire, UK) and Lowess normalisation carried out. Data was
then filtered below P,0.05 threshold and fold changes of greater
than 2 were deemed significant. Each condition was replicated at
least64 in duplicates.
Semi-quantitative PCR
RNA was extracted from DRG tissues using an RNeasy kit
(Qiagen Ltd, Crawley, UK) [17]. Each 25 ng of total RNA sample
was analysed on a 1% agarose gel at 3 cycle intervals to ensure
exponential PCR product amplification using the following
primers: GAPDH 59-AATGCATCCTGCACCACCAA-39 and
59-GTAGCCATATTCATTGTCATA-39; AMIGO3 59-CGGC
TGCGTGCCTTGTACCT-39 and 59-AGCACTTAGGCCCCG
CTGGT-39; p75 59-CCATCTTGGCTGCTGTGGTT-39 and
59-GCTGTTCCATCTCTTGAAAGCAA-39; NgR1 59-AAGTG
CTGCCAGCCAGATG-39 and 59-GCCTCCCGGGTTCCA
GTA-39; TROY/TAJ 59-CCCTCAATCCCGAAAACGA-39
and 59-TGGCCGCCACTGGAAT-39; LINGO-1 59-CTTT
CCCCTTCGACATCAAGAC-39 and 59-CAGCAGCACCAG
GCAGAA-39 (All synthesized by Alta Bioscience, University of
Birmingham, UK).
Immunohistochemistry
Perfusion-fixed L4/L5 DRG were cryoprotected through a
graded series of sucrose solutions and blocked in OCT (TAAB
Laboratories, Peterborough, UK). Cryosections of DRG were cut
10 mm thick, adhered onto charged glass slides and immunohis-
tochemistry performed as described by us previously [15,17].
Briefly, sections were washed, permeabilized in PBS containing
1% Triton X-100 (Sigma, Poole, UK) and blocked in PBS
containing 0.5% BSA (Sigma) and 0.05% Tween 20, followed by
incubation with the relevant antibody in a humidified chamber
overnight at 4uC. Primary antibodies included: goat anti-human
AMIGO, AMIGO2, AMIGO3 and TROY (all used at 1:100
dilution and from Santa Cruz Biotechnology, Santa Cruz, CA,
USA); monoclonal anti-NGFR (1:200 dilution; Sigma); rabbit anti-
NGFR1 (1:200 dilution; Alpha Diagnostics, San Antonio, TX,
USA); and rabbit anti-LINGO1 (1:400 dilution; Abcam, Cam-
bridge, UK). Sections were washed in PBS and incubated with
relevant secondary antibodies, diluted at 1:400 and coupled to
either Alexa Fluor 488 (green) or Texas Red (red) (both from
Invitrogen, Paisley, UK). Controls were included in each run for
each antibody that included omission of primary antibody and,
where available, pre-incubation with relevant blocking peptides
[15,17,24]. All controls showed no positive immunoreactivity.
Each immunohistochemistry run was performed in duplicate and
repeated on three separate occasions. Sections were viewed using a
Zeiss epi-fluorescent microscope (Carl Zeiss, Hertfordshire, UK)
and photomicrographs were captured using Axiovision Software
(Zeiss) and a Zeiss HRc camera (Zeiss).
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Cloning of full-length p75, TROY, NgR1 and AMIGO3 and
transfection of COS7 cells
Full length rat NgR1 p75, TROY and AMIGO3 (PubMed
accession numbers: NM_031831, NM_012610, NM_
DQ466087.1 and NM_178144.1, respectively) gene sequences
were PCR amplified and the p75 and TROY genes were cloned as
BglII/EcoRI fragments into a pCMV-HA plasmid (Invitrogen),
while AMIGO3 gene was cloned into the pCMV-Flag plasmid
(Invitrogen). Five cytoplasmic tail truncation mutants of full length
AMIGO3 (residues 1–508, transmembrane region 384–404) were
created by PCR using a common 59 forward primer and five
appropriate reverse primers (sequences available upon request).
This resulted in the following cytoplasmically truncated (CT)
constructs: AMIGO3 CT1 (1–409), CT2 (1–424), CT3 (1–444),
CT4 (1–464) and CT5 (1–484). Transfection of these constructs
into COS7 cells showed that AMIGO3 CT1 (cytoplasmic region
of 5 amino acids) was sufficient for efficient cell surface expression
and, for all experiments described in this manuscript, AMIGO3
CT1 refers to this construct. Expression constructs for each gene
were sequenced to confirm the correct sequence and reading
frame. COS7 cells were maintained in DMEM supplemented with
10% foetal calf serum and grown at 37uC in a humidified
atmosphere containing 5% CO2. To express target cDNA in
COS7 cells, 26106 cells were plated onto 100 mm dishes and
10 mg of pCMV-HA-p75, pCMV-Flag-AMIGO3, pCMV-Flag-
AMIGO3 CT1 and pCMV-NgR1 were co-transfected in different
combinations using Lipofectamine 2000, following the manufac-
turer’s guidelines (Invitrogen).
Immunoprecipitation and western blots
COS7 cells, transfected with combinations of Flag-AMIGO3,
NgR1 (untagged), p75-HA or TROY-HA, were harvested after
48 h and lysed in 1 ml ice-cold lysis buffer (50 mM HEPES
(pH 7.5), 150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 1% NP-
40 and 10% glycerol) for 30 min at 4uC. Cell lysates were then
cleared by centrifugation at 13,0006g for 15 min at 4uC.
Supernatants were incubated with Protein A/G-Sepharose beads
(Sigma) at 4uC for 1 hr and then incubated with either anti-Flag
M2 affinity gel (1:500 dilution; Sigma), anti-HA affinity matrix
(1:500 dilution; Roche, West Sussex, UK) or affinity purified
rabbit anti-NgR1 antibody (1:500 dilution; Alpha Diagnostics).
Beads were then washed 63 with lysis buffer, boiled in 26
Laemmli sample buffer for 4 min, subjected to 10% SDS-PAGE,
and analysed by western blotting with the following antibodies:
anti-Flag M2 (1:500 dilution; Sigma), anti-HA (1:500 dilution;
Roche) and anti-NgR1 (1:500 dilution; Alpha Diagnostics). Bands
were visualised with appropriate HRP-labelled anti-rabbit or anti-
mouse IgG (1:1000 dilution; GE Healthcare, Buckinghamshire,
UK) and the signal was developed using an ECL chemilumines-
cence kit following the manufacturer’s instructions (GE Health-
care).
For co-immunoprecipitation of endogenous target proteins from
rat (7 week old adult female Sprague-Dawley rat weighing 180 g)
and human brain (49 year old female who died from cardiac
arrest), 10 mg of each tissue was homogenised in ice-cold lysis
buffer (described earlier), centrifuged for 15 min at 13,0006g and
supernatants were stored until required. Dynabeads coated with
Protein G were then used to immunoprecipitate specific target
antigens according to the manufacturer’s instructions (Invitrogen).
Briefly, either 5 mg of goat anti-human AMIGO3 (1:500 dilution;
Santa Cruz Biotechnology) or rabbit anti-human NgR1 (1:500
dilution; Alpha Diagnostics) or monoclonal anti-NGFR (1:1000
dilution; Sigma) antibodies diluted in 200 ml PBS containing 0.1%
Tween 20 was incubated with gentle agitation for 10 min at room
temperature before harvesting the Dynabeads coated with relevant
antibodies (Dynabeads-Ab complex) by placing tubes in a
DynaMag-2 (Invitrogen). The bead supernatant was removed
and replaced with 750 ml of each lysate from brain tissue lysates
and incubated for 30 min at room temperature with gentle
agitation. Tubes were placed in the DynaMag-2 to collect the
Dynabeads-Ab-antigen complexes which were washed63 in PBS
and boiled in 26 Laemmli buffer for 4 min. Tubes were then
placed on the DynaMag-2 to collect the beads, supernatants
containing the proteins of interest were removed, resolved on 10%
SDS-PAGE gels and analysed by western blotting with relevant
antibodies (same dilutions as above) to AMIGO3, p75 and NgR1
as detailed above.
Densitometry
Western blots were scanned into Adobe Photoshop (Adobe
Systems Inc, San Jose, CA, USA) keeping all scanning parameters
the same between blots. Bands were then analysed using the built-
in-macros for gel analysis in ImageJ (NIH, USA, http://imagej.
nih.gov/ij), normalized to GAPDH or b-actin, where appropriate,
and means 6 SEM were plotted in Microsoft Excel (Microsoft
Corporation, CA, USA) [17,25,26,27].
Rho activation assay
COS7 cells were transfected with combinations of Flag-
AMIGO3, Flag-AMIGO3 CT1, NgR1 (untagged), HA-p75,
HA-TROY, as described previously. After 48 h, the transfected
cells were washed 63 in PBS and exposed to 10 mg/ml adult
Sprague-Dawley rat CNS myelin extracts (CME) (prepared as
described in [25]) for 15 min. Cells were then washed63 in PBS
and lysed with ice-cold lysis buffer (50 mM Tris-HCl (pH 7.5), 1%
Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 500 mM
NaCl, 10 mM MgCl2 and 5 mg/ml protease inhibitor cocktail
(Sigma)). GTP bound RhoA was assayed using a Rho pulldown
assay (Millipore, Watford, UK) and/or a colorimetric G-Lisa Rho
activation assay kit (Cytoskeleton Inc, Denver, CO, USA)
following the manufacturer’s instructions.
Adult rat DRG cell cultures
Dissociated mixed primary adult rat DRG cell cultures were
prepared from L4-L7 DRG pairs as described by us previously
[16,17]. Briefly, DRG cells were dissociated using collagenase
(Sigma), triturated to break up the digested tissues and cell debris
removed by centrifugation through a 15% bovine serum albumin
(Sigma) gradient. 500 DRGN/well were cultured on sterile glass 8-
well chamber slides (BD Biosciences, Oxford, UK) pre-coated with
poly-D-lysine and laminin-I (both from Sigma) either in the
presence or absence of 100 mg/ml CME [25] for at least 72 h. 5-
Table 1. Microarray analysis to show fold-differences in
mRNA levels compared to intact controls of described genes
in rat DRG 1 d after DC lesion.
Gene Description 1 d post-DC ± SEM
AMIGO Amphoterin induced Gene and ORF 1.0160.02
AMIGO2 Amphoterin induced Gene and ORF2 1.0260.01
AMIGO3 Amphoterin induced Gene and ORF3 4.0460.04***
LINGO1 Leucine Rich Repeat and Ig domain 1 1.0360.01
Mean values are shown from 4 different samples run in duplicate.
***P,0.0001.
doi:10.1371/journal.pone.0061878.t001
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fluoro-2-deoxyuridine (5-FDU) (Sigma) was added immediately
after plating cells at a final concentration of 30 mM to block glial
cell proliferation [25]. Fibroblast growth factor-2 (FGF2 from
Peprotech, London, UK) was used at a final concentration of
10 ng/ml to drive neurite outgrowth for 72 h [15,17,25,26].
Adult rat retinal cultures
Retina cultures containing RGC were dissociated from adult rat
retina (6–8 weeks old) using a papain system (Worthington
Biochemicals, New Jersey, USA), as described by us [22,24] and
1256103 dissociated cells were plated in 8-well chamber slides
(Beckton Dickinson) in supplemented Neurobasal-A (Invitrogen)
Figure 1. Levels of AMIGO at 1 day after DC injury. (A) Semi-quantitative RT-PCR and (B) densitometry to show changes in mRNA levels of
AMIGO isoforms and LINGO-1 expressed in non-regenerating DRGN compared to intact controls. GAPDH is used as a housekeeping gene. (C)
Representative western blots and (D) densitometry to show changes in protein levels of AMIGO isoforms and LINGO-1 in non-regenerating DRGN
relative to intact controls. (E–H) Immunohistochemistry in sections from intact controls and 1 d DC injured DRGN shows immunolabelling for AMIGO
(E), AMIGO2 (F), AMIGO3 (G) and (H) LINGO-1. Insets in E-H show images from blocking peptide controls to demonstrate specificity of the relevant
antibody Scale bars in E–H= 100 mm. *** = P,0.0001, ANOVA.
doi:10.1371/journal.pone.0061878.g001
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either in the presence or absence of CME (10 mg/ml) and CNTF
(10 ng/ml; Peprotech) with 30 mM 5-FDU for 72 h.
Immunocytochemistry
PBS washed DRG/retinal cultures were fixed in 4% formalde-
hyde, washed in PBS, blocked in PBS containing 0.5% BSA and
0.1% Tween 20, and incubated with the relevant antibody for 1 h
at room temperature in a humidified chamber, as described by us
previously [16]. Briefly, DRG/retinal cells were either double
stained for AMIGO3 (1:200 dilution; Santa Cruz) and bIII-tubulin
(1:200; Sigma) or bIII-tubulin alone (1:200 dilution; Sigma) to
detect neurite outgrowth for 1 h at room temperature. After
washing63 in PBS, cells were incubated with either Alexa 488 or
Texas Red-labelled relevant secondary antibodies. Cells were then
washed63 in PBS and mounted in Vectamount containing DAPI
(Vector Laboratories).
AMIGO3 siRNA and transfection
An siRNA sequence directed against AMIGO3 (siAMIGO3,
sense 59-TGGAGGAGCTGGAGAAGTT-39) was purchased
from Dharmacon (Colorado, USA) and 50 nM of siAMIGO3
was used to knock down AMIGO3 mRNA in DRGN/RGC in
mixed cultures, as described by us previously [15,17,25,28].
DRGN/RGC were also transfected with Lipofectamine alone
(control), a scrambled version of the above siAMIGO3 sequence
(scr-siAMIGO3; Dharmacon) and a non-specific siRNA targeting
green fluorescent protein (siGFP; Dharmacon) as controls.
Cultures were transfected for 5 hours prior to replacement of
the transfection medium with fresh Neurobasal-A with or without
CME/with or without FGF2/CNTF, as appropriate. After 72 h,
cultures were either fixed in 4% paraformaldehyde for immuno-
cytochemistry or lysed in ice-cold cell lysis buffer for western blot
or RhoGTP analyses. Each experiment was performed in triplicate
and repeated on 3 separate occasions. Western blot and
subsequent densitometry was used to quantify the extent of
AMIGO3 knockdown, as described above and by us previously
[17,24,25,28].
Measurement of neurite outgrowth and percentage of
DRGN/RGC with neurites
To measure neurite outgrowth, each well of an 8-well chamber
slide was divided into 9 equal quadrants and photographs were
captured randomly from these quadrants using Axiovision (Carl
Zeiss, Hertfordshire, UK). At least 30 bIII-tubulin+ DRGN/well
and all RGC with neurites were analysed to measure the longest
neurite for each DRGN/RGC using the built-in measurement
facilities in Axiovision software (Carl Zeiss), as described by us
previously [15,17,25]. Each data point, therefore, represents
measurements of at least 180 DRGN or RGC/condition.
To count the percentage of DRGN/RGC with neurites,
chamber slides were anonymised by a second investigator and
the number of DRGN/RGC with neurites were using a Zeiss
epifluorescent microscope (Carl Zeiss) scanning the entire well of
each 8-well chamber for each condition (n = 6 wells/condition).
Neurites were defined as bIII-tubulin+ processes emanating from
the DRGN/RGC cell body with lengths equal to or longer than
the DRGN/RGC diameter [25,26].
Statistical analysis
Each experiment was repeated on 3 independent occasions and
sample means were calculated for each variable and analysed for
significance by one-way analysis of variance (ANOVA) followed by
post-hoc testing with Dunnett’s method.
Results
AMIGO3 and not LINGO1 mRNA levels are significantly
elevated in DRGN 1 day after DC crush
At 1 day after DC injury, we found by microarray that
AMIGO, AMIGO-2 and LINGO-1 mRNA levels were not
modulated (Table 1), whilst AMIGO3 levels were significantly
elevated by 4-fold compared to intact control DRG (Table 1).
Semi-quantitative RT-PCR (Figure 1A and B) and western blot
(Figure 1C and D) analysis confirmed these changes at 1 day
after DC crush, demonstrating significant up-regulation of
AMIGO3 mRNA and protein levels (greater than 20-fold) when
compared to intact control, AMIGO and AMIGO2 (.4-fold
increase), with little or no change in LINGO-1 mRNA or protein
levels (Figure 1A–D). Immunohistochemistry for AMIGO
(Figure 1E), AMIGO2 (Fig. 1F), AMIGO3 (Fig. 1G) and
LINGO-1 (Fig. 1H) in sections of DRG taken at 1 day after DC
crush, mirrored changes observed for mRNA levels and demon-
strated that AMIGO3, but not AMIGO proteins were elevated in
DRGN. Together, these data indicate that AMIGO3 mRNA and
protein levels are significantly up-regulated above those of other
AMIGO isoforms and LINGO-1 at 1 day after DC injury.
At 10 days, AMIGO3 levels are significantly increased in
DRGN in the non-regenerating DC lesion model
Using microarray analysis at 10 days after injury, we found .8-
fold increase in DRG AMIGO3 mRNA in the non-regenerating
DC model, compared to intact controls (Table 2). In the SN
paradigm (peripheral nerve regeneration paradigm), DRG AMI-
GO3 levels were less, at .3.5-fold higher than those of intact
controls, while in the regenerating pSN+DC paradigm, AMIGO3
mRNA was unchanged compared to intact controls (Table 2). At
this later sub-acute time point, DRG LINGO-1 mRNA levels had
risen by 2-fold in the non-regenerating DC model compared to
those in intact control DRG. All these changes were confirmed by
semi-quantitative RT-PCR and subsequent densitometric analysis
(Figure 2A–D).
Little or no changes in levels of AMIGO and AMIGO2 protein
were detected in DRGN from non-regenerating DC and
regenerating SN and pSN+DC models by immunohistochemistry
(not shown). Very low levels of AMIGO3 protein were detected in
DRGN from intact control DRG (Figure 2E–G), while higher
levels of AMIGO3 were observed in DRGN from the non-
Table 2. Microarray analysis to show fold-differences in
mRNA levels of described genes compared to intact controls
in rat DRG 10 d after DC lesion, sciatic nerve (SN) or pre-
conditioning (pSN+DC) lesions.
Gene Description DC SN pSN+DC
AMIGO Amphoterin induced
Gene and ORF
1.7760.01 1.0260.02 1.0360.02
AMIGO2 Amphoterin induced
Gene and ORF2
1.8560.04 1.0160.02 1.0260.05
AMIGO3 Amphoterin induced
Gene and ORF3
8.3060.02*** 3.6160.04 1.0460.03
LINGO1 Leucine Rich Repeat
and Ig domain 1
2.0660.02 1.0160.01 1.0560.01
Mean 6 SEM values are shown from 4 different samples run in duplicate.
***P,0.0001.
doi:10.1371/journal.pone.0061878.t002
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regenerating DC model (Figure 2H–J). Double immunohisto-
chemistry for neurofilament-200 and AMIGO3 also showed that
AMIGO3 localisation (inset to Figure 2H) was not restricted to
DRGN but also present in DRG glia, including satellite cells (inset
to Fig. 2J). In the regenerating SN paradigm however, lower levels
of AMIGO3+ staining were apparent in DRGN compared to
those seen in DRGN in non-regenerating DCmodels (Figure 2K–
M). By contrast, DRGN in the regenerating pSN+DC model had
low levels of AMIGO3 immunostaining, similar to the low levels
detected in intact controls (Figure 2N–P). A blocking peptide
control demonstrated specificity of the AMIGO3 antibodies used
in this study (Figure 2Q–S). The differences in immunohisto-
chemistry patterns between models were corroborated by western
blotting of DRG protein lysates (Figure 2T) and densitometric
Figure 2. AMIGO3 levels at 10 days in intact controls, non-regenerating DC, and regenerating SN and pSN+DC models. (A), (C) Semi-
quantitative RT-PCR and (B), (D) densitometry was used to quantify AMIGO3 and LINGO-1 expression levels using total RNA extracted from
appropriately treated or untreated DRG. (E–S) Immunohistochemistry, (T) western blotting and (U) densitometry to show high levels of AMIGO3
localisation in DRGN from non-regenerating DC models compared to those in regenerating SN and pSN+DC models. High power insets in (H) and (J)
show neuronal and glial localisation of AMIGO3 in sections double stained with Neurofilament 200 and AMIGO3 (arrowhead). Blocking peptide
control (Q–S) shows the specificity of AMIGO3 antibodies used. Scale bar = 100 mm. *** =p,0.0001, ANOVA.
doi:10.1371/journal.pone.0061878.g002
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quantification (Figure 2U), confirming that at 10 days signifi-
cantly lower levels of AMIGO3 were present in DRG tissue in
regenerating SN and pSN+DC lesioned models compared to the
non-regenerating model. Although the SN model represents a
regenerating model, DRGN had significantly higher levels of
AMIGO3 in this paradigm compared to the regenerating
pSN+DC lesion model, suggesting that disinhibition is achieved
in the SN model by alternative and currently unknown
mechanisms.
Very low levels of LINGO-1 protein were observed by
immunohistochemistry at 10 days after injury in both non-
regenerating and regenerating DRGN from DC or SN axotomy
models, respectively, compared to intact controls (Figure 3A–O).
Despite LINGO-1 being co-localised with AMIGO3 (Figure 3P–
S) and LINGO-1 mRNA levels being 2-fold elevated in the non-
regenerating DC model, LINGO-1 protein levels did not change
and were not correlated with the DRGN regeneration state nor
with AMIGO3 expression during the 1–10 day period studied
(Figure 3T). Thus, AMIGO3 is likely to be more important than
LINGO-1 in mediating the inhibition of DRGN axon regenera-
tion at least over the first 10 d after DC axotomy.
Depressed AMIGO3 levels correlate with RGC axon
regeneration
To confirm our findings in the DRGN injury model, we
investigated the dynamic expression levels of AMIGO3 in the ON-
RM and ON-NRM and observed that AMIGO3 levels were
significantly higher in the ON-NRM and suppressed in the ON-
RM at 6, 8 and 20 days after ON crush injury by western blotting
and densitometry (Figure 4A and B). Immunohistochemistry
demonstrated a high frequency of AMIGO3+ RGC in the ON-
NRM while low levels were detected in a small number of RGC in
ON-RM retinae (Figure 4C). Double immunolocalisation of
AMIGO3 with bIII-tubulin confirmed that AMIGO3 was
expressed in bIII-tubulin+ RGC (high power insets in
Fig. 4C). These results confirmed our findings in the DC injury
model and demonstrated that low levels of AMIGO3 also
correlated with RGC axon regeneration the ON injury model.
In light of the in vivo observations in the DRGN and ON injury
models, we next investigated the possibility that AMIGO3 could
substitute for LINGO-1 in the NgR1-p75/TROY inhibitory
signalling complex.
AMIGO3 interacts with NgR1 and p75 in transfected
COS7 cells and endogenous rat and human brain lysates
To determine whether AMIGO3 is a co-receptor for the NgR1-
p75 receptor complex, we transfected COS7 cells with combina-
tions of full length Flag-tagged AMIGO3, NgR1 and HA-tagged
p75 genes. We confirmed expression of the relevant proteins by
western blotting in cell lysates (Figure 5A). Co-immunoprecipi-
tation and western blotting for relevant proteins in cells transfected
with Flag-AMIGO3, NgR1 and HA-p75 gene combinations
demonstrated interaction between AMIGO3, NgR1 and p75 only
when all three receptors were co-transfected (Figure 5B).
Co-immunoprecipitation, followed by western blotting with
relevant antibodies, also showed positive bands and hence binding
between NgR1-p75-AMIGO3 protein combinations in both rat
and human brain lysates (Figure 5C). These results demonstrate
that AMIGO3, NgR1 and p75 interact appropriately to form a
receptor complex in both transfected cells and in brain extracts
containing native co-receptor partners.
RhoA activation in NgR1-p75/TROY-AMIGO3 transfected
COS7 cells
In either untransfected COS7 cells, or those transfected with
full-length NgR1 and p75 or p75 and AMIGO3 genes together,
Rho was not activated either in the presence or absence of CME
(Figure 6A and B). In the presence of CME, transfection with all
three receptors, NgR1, p75 and AMIGO3 genes, conferred
responsiveness to CME as evidenced by significantly enhanced
RhoGTP levels, detected by both Rho pulldown (Figure 6A) and
colorimetric RhoGTP assays (Figure 6B). Transfection of
AMIGO3 along with NgR1 and TROY genes also conferred
CME responsiveness similar to that of the NgR1-p75-AMIGO3
genes (Figure 6C). Furthermore, transfection with a cytoplasmic
tail deleted AMIGO3 (AMIGO3 CT1) with NgR1 and p75 also
conferred CME responsiveness of cells. (Figure 6C). Our results
demonstrate that AMIGO3 forms a functional complex with
NgR1 and p75/TROY to confer responsiveness to CME and that
only the extracellular portion of AMIGO3 is required for this
functional interaction.
Figure 3. LINGO1 levels in intact, non-regenerating DC and
regenerating (SN and pSN+DC lesioned) DRGN models 10 days
after injury. High power insets in (D) and (F) show neuronal and glial
localisation of AMIGO3. (P–S) Co-localisation of LINGO-1 with AMIGO3
in DRGN from non-regenerating DC models. (T) Western blotting of
LINGO-1 levels in DRG in our experimental model paradigms showing
low and unchanged levels of LINGO-1 compared to a positive control
lane using rat brain lysates. b-actin was used as a loading control. Scale
bars = 100 mm.
doi:10.1371/journal.pone.0061878.g003
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Knockdown of AMIGO3 promotes disinhibited DRGN
neurite outgrowth in the presence of CME only when
stimulated with FGF-2
In dissociated primary adult DRG cultures containing axoto-
mised DRGN, we confirmed immunolocalisation of AMIGO3
protein in .95% of bIII-tubulin+ DRGN (Figure 7A and B).
Transfection of DRG cells with siAMIGO3 knocked down
AMIGO3 protein levels by 80% (Figure 7C), while no changes
in AMIGO3 levels were detected in either untreated cultures or
those treated with Scr-siAMIGO3, or siGFP. Transfection of
DRG cultures with siAMIGO3 did not affect protein levels of
AMIGO, AMIGO2 or LINGO-1, suggesting that the siAMIGO3
was specific to AMIGO3 (Figure 7C). In the presence of CME,
RhoGTP levels detected by Rho pulldown assay, were high in
untransfected DRG cells and after transfection with Scr-
siAMIGO3 (Figure 7D and E). However, in DRG cells
transfected with either siAMIGO3 or siAMIGO3+FGF-2,
RhoGTP levels were either low or absent (Figure 7D and E).
In the absence of CME, untransfected DRG or those transfected
with Scr-siAMIGO3, siAMIGO3 or siAMIGO3+FGF2, did not
activate Rho (Figure 7D and E). These results suggest that
knockdown of siAMIGO3 disables the axon growth inhibitory
signalling cascade through suppression of RhoA activation that is
normally induced by CNS myelin ligands, leading to disinhibition
of DRGN neurite outgrowth.
The physiological role of AMIGO3 in blocking neurite
outgrowth was confirmed in adult rat DRG cultures. The modest
neurite outgrowth seen in untreated DRG cultures (Figure 8A(i))
is enhanced by treatment with FGF-2 (Figure 8A(ii)), but
inhibited by addition of CME (Figure 8A(iii)). Neither FGF-2
(Figure 8A(iv)) nor siAMIGO3 (Figure 8A(v)) treatments alone
overcame CME-mediated inhibition. However, the addition of
FGF-2 with siAMIGO3 to CME-inhibited cultures promoted
vigorous neurite outgrowth (Figure 8A(vi)), with enhanced
numbers of DRGN (Figure 8B) growing longer neurites
(Figure 8C) compared to untreated and FGF-2-treated DRGN.
In the absence of CME, siAMIGO3+FGF2 treatment causes
equally robust neurite outgrowth as siAMIGO3+FGF2 in CME-
inhibited cultures (Figure 8B and C). Taken together, these
results demonstrate that siAMIGO3 paralyses the inhibitory
NgR1-p75 signalling cascade in the presence of CME and
disinhibits DRGN but, despite disinhibition, DRGN neurite
outgrowth does not occur unless driven by FGF-2.
Figure 4. Suppressed levels of AMIGO3 correlate with optic nerve regeneration. (A) Representative western blot of AMIGO3 in NRM and
RM at 0, 6, 8 and 20 days after ONC and (B) densitometry to show higher levels of AMIGO3 in NRM at 6, 8 and 20 days after ONC. b-actin was used as a
protein loading control. (C) Immunohistochemistry to show that high levels of AMIGO3 is expressed in the majority of RGC in NRM (e.g. arrows) while
lower levels are present in RGC from RM retinae. Insets show co-localisation of bIII-tubulin with AMIGO3 (arrowheads). Scale bar in (C) = 100 mm, in
insets = 20 mm. *** = P,0.0001, ANOVA.
doi:10.1371/journal.pone.0061878.g004
AMIGO3 Is a NgR1/p75 Co-Receptor in the CNS
PLOS ONE | www.plosone.org 8 April 2013 | Volume 8 | Issue 4 | e61878
Knockdown of AMIGO3 promotes disinhibited RGC
neurite outgrowth in the presence of CME, when
stimulated with CNTF
In dissociated adult rat retinal cultures, we first confirmed
expression of AMIGO3, before knockdown with the same
siAMIGO3 as was used for DRG cultures. We confirmed that
.95% of bIII-tubulin+ RGC were AMIGO3+ (Figure 9A and
B). The RGC neurite outgrowth observed in CNTF treated retinal
cultures (Figure 9C(i)) was blocked by the addition of an
Figure 5. AMIGO3 interacts with NgR1 and p75. (A) Western blot
of COS-7 total cell lysates extracted 48 h after transfection with
combinations of FLAG-AMIGO3, HA-p75 and NgR1 genes. (B) Co-
immunoprecipitation of AMIGO3, NgR1 and p75 detected after western
blotting for relevant anti-HA, anti-FLAG or rabbit anti-NgR1 antibodies
from COS-7 cells co-expressing combinations of Flag-AMIGO3, NgR1
and HA-p75. (C) Co-immunoprecipitation of AMIGO3, NgR1 and p75
from adult rat and human brain lysates using combinations of goat anti-
AMIGO3, rabbit anti-NgR1 and mouse anti-p75 antibodies for immu-
noprecipitation (IP) and western blotting (WB). IgG was used as a
control antibody for IP and GAPDH was used as a loading control.
doi:10.1371/journal.pone.0061878.g005
Figure 6. Co-transfection of AMIGO3, NgR1 and p75 activates
RhoA. (A) RhoGTP levels detected by a Rho pulldown assay in control
untransfected and transfected COS-7 cells expressing NgR1-p75 and
NgR1-p75-AMIGO3 genes, in the presence (+) and absence of CME (2).
Total Rho levels were also detected by western blotting. (B)
Colorimetric Rho activation assay in untransfected control and in
COS7 cells transfected with NgR1-p75 and NgR1-p75-AMIGO3 gene
combinations in the presence of CME (+). (C) Colorimetric Rho
activation assay in untransfected control COS7 cells and cells
transfected with NgR1-TROY-AMIGO3, NgR1-p75-AMIGO3 CT1-2 genes,
in the presence of CME (+).
doi:10.1371/journal.pone.0061878.g006
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inhibitory concentration of CME (Figure 9C(ii)). However,
knockdown of AMIGO3 alone (Figure 9C(iii)) did not disinhibit
RGC neurite outgrowth in the presence of CME, but stimulation
with CNTF after AMIGO3 knockdown promoted significant
disinhibited RGC neurite outgrowth in many RGC
(Figure 9C(iv) and Figure 9D) which grew longer neurites
(Figure 9E) compared to untreated or CNTF treated cultures.
Knockdown of AMIGO3 in the absence of CME and stimulated
with CNTF also produced similar RGC neurite outgrowth as
cultures treated with siAMIGO3+CME+FGF2 (Figure 9D and
Figure 7. AMIGO3 is localised in DRGN and its suppression using siAMIGO3 in the presence of CME prevents Rho activation. (A)
Representative AMIGO3 localisation in DRGN (arrows=AMIGO3+, arrowhead=AMIGO32) and (B) quantification of the percentage 6 SEM of DRGN
which are AMIGO3+ and AMIGO32, in DRG cultures. (C) Western blotting and densitometry showing the levels of knockdown, compared to Scr-
siAMIGO3 and siGFP after siAMIGO3 treatment. Re-stripped western blots are also shown for AMIGO, AMIGO2 and LINGO-1 to demonstrate that
knockdown of AMIGO3 does not affect the levels of these molecules in culture. b-actin is used as a loading control. (D) Rho activation assay in
untransfected and siRNA transfected DRG cells in the presence of CME. Total Rho levels were also detected by western blotting. Scale bar in
(A) = 50 mm.
doi:10.1371/journal.pone.0061878.g007
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E). These results demonstrated that AMIGO3 knockdown in the
presence of CME also disinhibits RGC cultures but requires an
appropriate neurotrophic factor to drive neurite outgrowth.
Discussion
Although LINGO-1 is an accepted co-receptor in the NgR1-
p75/TROY receptor complex signalling CNS axon growth
inhibition, its expression patterns after spinal cord injury are not
consistent with its proposed function. Since LINGO-1 levels do
not rise appreciably in DRGN until 14 days after injury [10], we
postulated that other molecules may take part in signalling axon
growth inhibition in the acute phase after injury. In bioinformatic
screens from microarray data derived from DRGN of regenerating
and non-regenerating DC injury models, we identified AMIGO3
as a possible regeneration-related molecule. Here, we show that
AMIGO3 interacts with NgR1, p75 and TROY to constitute a
functional receptor complex for CNS myelin-derived inhibitory
ligands that activates RhoA and controls axon growth and
extension.
We demonstrate a novel role for AMIGO3 as a molecule that
participates in the NgR1-p75/TROY receptor complex that
signals axon growth inhibition and show that its expression levels
are consistent with a physiological function in this complex in the
injured CNS. Accordingly, we observed that AMIGO3 mRNA
and protein levels were significantly raised in axotomised DRGN
in non-regenerating DC lesion models above those seen in
regenerating SN and pSN+DC lesioned DRGN from 1 day
through to at least 10 days after injury. By contrast, LINGO-1
mRNA and protein remained low acutely and were not modulated
between regenerating and non-regenerating paradigms. Since our
results showed that AMIGO3 expression levels were significantly
higher than those of LINGO-1 in centrally axotomised DRGN
and that LINGO-1 was not modulated between regenerating versus
non-regenerating injury paradigms, we suggest that AMIGO3
may be the preferred receptor partner of the NgR1-p75/TROY
axon growth inhibitory signalling complex in the early phase of
CNS injury responses. We also confirmed our findings in the
DRGN injury model and in our well-established regenerating and
non-regenerating ONC injury models [19,20,22,24,26], where we
demonstrated that AMIGO3 levels were elevated in the non-
regenerating ON injury model while levels remained low in
regenerating ON injury model retinae.
We further show that AMIGO3 interacted with NgR1-p75/
TROY in both transfected COS7 cells and in rat and human
brain lysates to constitute functional receptor complexes that
activated RhoA in response to CNS myelin. This suggests a
physiological role of AMIGO3 in mediating myelin-induced axon
growth inhibition. The critical role of AMIGO3 in blocking
neurite outgrowth was confirmed in both adult rat primary DRG
and retinal cultures. Accordingly, siRNA silencing of AMIGO3
paralysed signalling by the NgR1-p75/TROY receptor complex,
as evidenced by non-activation of RhoGTP in the presence of
CME. Despite this apparent disinhibition of DRGN and RGC,
neurite outgrowth did not occur unless driven by an appropriate
neurotrophic factor, such as FGF-2 or CNTF. The choice of
neurotrophic factor depends on the particular population of
neurons under investigation. For example, we have shown that
cultured DRG respond optimally to FGF2 [15,17,25]; while RGC
Figure 8. Knockdown of AMIGO3 promotes DRGN neurite
outgrowth in the presence of CME. (A) Representative photomi-
crographs of bIII-tubulin+ DRGN neurite outgrowth in untransfected
and siRNA transfected DRG cells in the presence or absence of CME with
or without FGF-2 6 SEM. Quantification of (B) mean number of DRGN
with neurites 6 SEM and (C) mean neurite length after treatment with
AMIGO3 in the presence of CME, with and without FGF-2 6 SEM.
*** = P,0.0001, ANOVA. Scale bar in (A) = 100 mm.
doi:10.1371/journal.pone.0061878.g008
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respond to CNTF [22,30,31] and hence these same factors were
used in our current study.
The results from both DRG and RGC culture models are
consistent with our previous observations that disinhibition alone is
not sufficient to promote neurite outgrowth in the presence of
CNS myelin but that addition of appropriate neurotrophic factors
is required to drive growth. For example, DRGN neurites that
were disinhibited by a variety of strategies required either FGF-2
[16,17,25], or combinations of nerve growth factor (NGF), brain-
derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) to
elongate neurites [15]. Likewise, RGC neurites that were also
disinhibited by a variety of strategies required either combinations
of neurotrophic factors such as FGF-2, BDNF and NT-3 [26,24]
or ciliary neurotrophic factor alone to grow neurites [22,24,29].
Others have also shown that combining disinhibition with a
neurotrophic drive results in enhanced CNS axon regeneration
[30,31,32].
In summary, our results support a novel role for AMIGO3 as a
preferred and mandatory partner in the NgR1-p75/TROY
receptor complex that acutely signals the inhibitory effects of
CNS myelin-derived ligands. Suppression of AMIGO3 function
rather than LINGO-1, when combined with NTF, would be a
more effective acute therapeutic strategy to promote CNS axon
regeneration.
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Figure 9. Knockdown of AMIGO3 promote RGC neurite outgrowth in the presence of inhibitory concentration of CME. (A)
Immunocytochemistry and (B) quantitation to show that .95% of RGC were AMIGO3+ (arrow) while a small proportion of RGC were AMIGO2
(arrowheads). (C) Representative photomicrographs of bIII-tubulin+ RGC neurite outgrowth in CNTF and siRNA transfected retinal cells in the
presence and absence of CME with or without CNTF. Quantification of (D) mean proportion of RGC with neurites and (E) mean neurite length after
treatment with siAMIGO3 in the presence of CME, with and without CNTF. *** = P,0.0001, ANOVA. Scale bars in (A) = 50 mm and (C) = 100 mm.
doi:10.1371/journal.pone.0061878.g009
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